Search - tctmd.com

Displaying 1 - 9 of 9

Sort: Relevancy | Date

News Conference News ACC 2019

Dropping Aspirin: Two Trials Explore P2Y12 Monotherapy After Short-term DAPT Post-PCI

Yael L. Maxwell

March 18, 2019

News Conference News ACC 2017

ABSORB III: Two-Year Results Show a Higher MACE Rate Compared With Xience

Michael O'Riordan

March 18, 2017

News Conference News ACC 2014

NEXT at 2 Years: Nobori DES Still Noninferior to Xience/Promus

Jason Kahn

March 31, 2014

Presentation ACC 2013

Three-Year Results of the PLATINUM Randomized Trial Comparing Platinum Chromium PROMUS Element and Cobalt Chromium PROMUS/XIENCE V Everolimus-Eluting Stents

Presenter: Ian T. Meredith

March 09, 2013

News Conference News ACC 2013

Is Nobori NEXT? Biodegradable-Polymer DES Noninferior to EES

Jason Kahn

March 09, 2013

News Conference News ACC 2013

Pair of Studies Show Positive Stent Results at ACC

Yael L. Maxwell

March 08, 2013

Presentation ACC 2012

Two-Year Results of the PLATINUM Randomized Trial Comparing Platinum Chromium PROMUS Element and Cobalt Chromium PROMUS/XIENCE V Everolimus-Eluting Stents in De Novo Coronary Artery Lesions

Presenter: Gregg Stone

March 28, 2012

News Conference News ACC 2012

RESOLUTE: Zotarolimus-Eluting Stent Fares Well at 2 Years

March 26, 2012

News Conference News ACC 2012

Three Months of Antiplatelet Therapy with Endeavor Equal to 1 Year with Other DES

Jason Kahn

March 24, 2012

Advertisement

Dropping Aspirin: Two Trials Explore P2Y12 Monotherapy After Short-term DAPT Post-PCI

ABSORB III: Two-Year Results Show a Higher MACE Rate Compared With Xience

NEXT at 2 Years: Nobori DES Still Noninferior to Xience/Promus

Three-Year Results of the PLATINUM Randomized Trial Comparing Platinum Chromium PROMUS Element and Cobalt Chromium PROMUS/XIENCE V Everolimus-Eluting Stents

Is Nobori NEXT? Biodegradable-Polymer DES Noninferior to EES

Pair of Studies Show Positive Stent Results at ACC

Two-Year Results of the PLATINUM Randomized Trial Comparing Platinum Chromium PROMUS Element and Cobalt Chromium PROMUS/XIENCE V Everolimus-Eluting Stents in De Novo Coronary Artery Lesions

RESOLUTE: Zotarolimus-Eluting Stent Fares Well at 2 Years

Three Months of Antiplatelet Therapy with Endeavor Equal to 1 Year with Other DES

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content